|
WO2021005232A1
|
|
Intranasal administration of neutralising antiviral antibodies
|
|
WO2020201527A1
|
|
Modified immune receptor constructs
|
|
WO2020197400A1
|
|
Engineered iga antibodies and methods of use
|
|
WO2020091596A1
|
|
Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils
|
|
EP3811945A1
|
|
Compounds for treating and preventing growth hormone receptor-dependent conditions
|
|
WO2020080941A1
|
|
Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
|
|
WO2020067897A1
|
|
Vascoscope
|
|
NL2023291B1
|
|
Hydrogel for in-vivo release of medication
|
|
WO2019219979A1
|
|
Compositions and methods for cell targeting therapies
|
|
EP3773724A2
|
|
Drug combinations for use in the treatment of ras-mutant cancer
|
|
NL2022890B1
|
|
Parameter map determination for time domain magnetic resonance
|
|
AU2019241439A1
|
|
Targeted thrombolysis for treatment of microvascular thrombosis
|
|
WO2019156566A1
|
|
Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
|
|
CA3085420A1
|
|
Methods for preparing nucleic acid molecules for sequencing
|
|
NL2021720B1
|
|
Vascoscope
|
|
EP3684818A2
|
|
Anti-gd2 antibody for the treatment of neuroblastoma
|
|
WO2020020471A1
|
|
Ascl2-responsive reporters for labeling of intestinal stem cell activity
|
|
NL2021191B1
|
|
A tool system for removing prosthetic cement from a bone of a patient undergoing a joint prosthesis replacement operation
|
|
EP3624823A1
|
|
Compositions and methods for cell targeting therapies
|
|
WO2018190713A1
|
|
Inhibitors of lysine methyltransferase for treatment of pain
|
